Technical Analysis for AVXL - Anavex Life Sciences Corp.

Grade Last Price % Change Price Change
B 20.95 -0.14% -0.03
AVXL closed down 6.0 percent on Friday, July 23, 2021, on 62 percent of normal volume.
Earnings due: Aug 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical AVXL trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion -0.14%
NR7 Range Contraction -6.14%
Lower Bollinger Band Walk Weakness -6.14%
Oversold Stochastic Weakness -6.14%
Bullish Engulfing Bullish -7.59%
Lower Bollinger Band Walk Weakness -7.59%
Lower Bollinger Band Touch Weakness -7.59%
Oversold Stochastic Weakness -7.59%
Stochastic Buy Signal Bullish -0.05%
1,2,3 Pullback Bullish Bullish Swing Setup -0.05%
Older End-of-Day Signals for AVXL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % 7 minutes ago
Down 1% 7 minutes ago
60 Minute Opening Range Breakdown 3 days ago
Down 5% 3 days ago
Down 3% 3 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Anavex Life Sciences Corp. Description

Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer's disease. The company's product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Cancers Chemical Compounds Neuroscience Alzheimer's Disease Alzheimer's Central Nervous System Disease Central Nervous System Diseases Piperidines Treatment Of Alzheimer's Disease Lewy Body Dementia Neuroprotection Donepezil Nootropics

Is AVXL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.5
52 Week Low 3.6543
Average Volume 3,032,869
200-Day Moving Average 11.48
50-Day Moving Average 18.87
20-Day Moving Average 23.79
10-Day Moving Average 22.58
Average True Range 2.12
ADX 38.44
+DI 25.97
-DI 22.10
Chandelier Exit (Long, 3 ATRs) 25.15
Chandelier Exit (Short, 3 ATRs) 26.62
Upper Bollinger Bands 27.58
Lower Bollinger Band 19.99
Percent B (%b) 0.13
BandWidth 31.91
MACD Line 0.48
MACD Signal Line 1.19
MACD Histogram -0.7143
Fundamentals Value
Market Cap 1.26 Billion
Num Shares 60.2 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -35.08
Price-to-Sales 0.00
Price-to-Book 12.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.77
Resistance 3 (R3) 25.01 24.00 24.14
Resistance 2 (R2) 24.00 23.03 23.87 23.93
Resistance 1 (R1) 22.49 22.44 21.98 22.24 23.72
Pivot Point 21.47 21.47 21.22 21.35 21.47
Support 1 (S1) 19.96 20.51 19.45 19.72 18.24
Support 2 (S2) 18.95 19.91 18.82 18.03
Support 3 (S3) 17.44 18.95 17.82
Support 4 (S4) 17.19